Shares of LivaNova LIVN were unchanged after the company reported Q1 results.
Quarterly Results
Earnings per share rose 6.06% year over year to $0.35, which beat the estimate of $0.15.
Revenue of $247,600,000 rose by 2.15% year over year, which beat the estimate of $232,300,000.
Looking Ahead
LivaNova hasn't issued any earnings guidance for the time being.
LivaNova hasn't issued any revenue guidance for the time being.
How To Listen To The Conference Call
Date: Apr 28, 2021
Time: 07:00 AM
ET Webcast URL: https://edge.media-server.com/mmc/p/ah4w6462
Recent Stock Performance
Company's 52-week high was at $85.17
Company's 52-week low was at $41.07
Price action over last quarter: Up 8.06%
Company Description
U.K.-based LivaNova was born of a combination between Cyberonics in the U.S. and Sorin in Italy. The medical device firm is primarily focused on cardiovascular and cardiopulmonary solutions (with surgical heart valves, heart-lung machines, and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. LivaNova derives roughly half of its revenue from the U.S. market, another 21% from Europe, and the remainder from the rest of the world.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
